Company intelligence / Profile preview
Pneumagen
St Andrews, Fife, United Kingdompneumagen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neumifil demonstrated a clinically significant reduction in the incidence and severity of symptomatic influenza infection in a Phase 2 human challenge study. The drug was well tolerated with no new safety signals compared to placebo. Further studies are planned to evaluate efficacy in patients with chronic lung disease at risk of viral-induced exacerbations.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Engineered multivalent Carbohydrate Binding Modules (mCBMs)Intranasal antivirals
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
hVIVO/Open Orphan plc – conducting human challenge studies for clinical trialsFUJIFILM Diosynth Biotechnologies – supporting process development and scale-up manufacturing for clinical trials
Beyond the preview
Go deeper on Pneumagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pneumagen.